First‐line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation‐positive non‐small cell lung cancer

פריטים דומים

• Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer
  מאת: Su, Po-Lan, et al.
  יצא לאור: (2018)
• Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan
  מאת: Yang, Szu-Chun, et al.
  יצא לאור: (2020)
• Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
  מאת: Sullivan, Ivana, et al.
  יצא לאור: (2017)
• The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer
  מאת: Su, Vincent Yi-Fong, et al.
  יצא לאור: (2020)
• Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter prospective SMILE study
  מאת: Wei, Yu-Feng, et al.
  יצא לאור: (2019)